Dupilumab-induced ocular surface disease: a primer

Drug Ther Bull. 2024 Jan 30;62(2):27-31. doi: 10.1136/dtb.2023.249019rep.

Authors

Merin Anna Reji¹, Aaisha Haque², Supriya Goyal³, Guha Krishnaswamy⁴

Affiliations

¹ Internal Medicine, Wake Forest Baptist Health, Winston-Salem, North Carolina, USA.
² W. G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina, USA.
³ Private Practice, Baltimore, Maryland, USA.
⁴ Wake Forest School of Medicine, Winston-Salem, North Carolina, USA gkrishna@wakehealth.edu.

PMID: 37402544
DOI: 10.1136/dtb.2023.249019rep

No abstract available

Keywords: Dermatology; Eye; Immunology; Ophthalmology; Unwanted effects / adverse reactions.

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized